Investors sue First Foundation, Akero Therapeutics over merger deals.

Halper Sadeh LLC is investigating First Foundation Inc. (NYSE: FFWM) and Akero Therapeutics, Inc. (NASDAQ: AKRO) for potential violations of federal securities laws and breaches of fiduciary duties. First Foundation shareholders may have limited time to enforce their rights after the sale to FirstSun Capital Bancorp. Akero shareholders may be entitled to a cash payment of $54.00 per share and a Contingent Value Right entitling them to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin by June 30, 2031.